title: Crosslinked multilamellar liposomes for controlled delivery of anticancer drugs.
abstract: Liposomes constitute one of the most popular nanocarriers for the delivery of cancer therapeutics. However, since their potency is limited by incomplete drug release and inherent instability in the presence of serum components, their poor delivery occurs in certain circumstances. In this study, we address these shortcomings and demonstrate an alternative liposomal formulation, termed crosslinked multilamellar liposome (CML). With its properties of improved sustainable drug release kinetics and enhanced vesicle stability, CML can achieve controlled delivery of cancer therapeutics. CML stably encapsulated the anticancer drug doxorubicin (Dox) in the vesicle and exhibited a remarkably controlled rate of release compared to that of the unilamellar liposome (UL) with the same lipid composition or Doxil-like liposome (DLL). Our imaging study demonstrated that the CMLs were mainly internalized through a caveolin-dependent pathway and were further trafficked through the endosome-lysosome compartments. Furthermore, in vivo experiments showed that the CML-Dox formulation reduced systemic toxicity and significantly improved therapeutic activity in inhibiting tumor growth compared to that of UL-Dox or DLL-Dox. This drug packaging technology may therefore provide a new treatment option to better manage cancer and other diseases.
authors: Mork Family Department of Chemical Engineering and Materials Science, University of Southern California, Los Angeles, CA 90089, USA.
authors: Kye-Il
authors: KI
authors: Joo
authors: Liang
authors: L
authors: Xiao
authors: Shuanglong
authors: S
authors: Liu
authors: Yarong
authors: Y
authors: Liu
authors: Chi-Lin
authors: CL
authors: Lee
authors: Peter S
authors: PS
authors: Conti
authors: Michael K
authors: MK
authors: Wong
authors: Zibo
authors: Z
authors: Li
authors: Pin
authors: P
authors: Wang
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D004337:Drug Carriers; D005260:Female; D006367:HeLa Cells; D006801:Humans; D008081:Liposomes; D051379:Mice; D008810:Mice, Inbred C57BL
chemical_list: D000970:Antineoplastic Agents; D004337:Drug Carriers; D008081:Liposomes
references: Radiat Res. 1996 May;145(5):542-53
references: 8619019
references: Clin Cancer Res. 2001 Feb;7(2):223-5
references: 11234871
references: Nat Rev Drug Discov. 2008 Sep;7(9):771-82
references: 18758474
references: Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
references: 2946403
references: Biochim Biophys Acta. 2004 May 27;1663(1-2):167-77
references: 15157619
references: J Control Release. 2006 Feb 21;110(3):490-504
references: 16387383
references: Nat Rev Clin Oncol. 2010 Nov;7(11):653-64
references: 20838415
references: Biochim Biophys Acta. 2007 Jun;1768(6):1367-77
references: 17400180
references: Nat Mater. 2011 Mar;10(3):243-51
references: 21336265
references: Clin Breast Cancer. 2003 Dec;4(5):318-28
references: 14715106
references: J Pharm Sci. 2008 Nov;97(11):4696-740
references: 18351638
references: Clin Pharmacokinet. 2003;42(5):419-36
references: 12739982
references: Nat Rev Mol Cell Biol. 2007 Mar;8(3):185-94
references: 17318224
references: Nat Rev Mol Cell Biol. 2007 Aug;8(8):603-12
references: 17609668
references: Nat Nanotechnol. 2007 Dec;2(12):751-60
references: 18654426
references: Cell. 2004 Sep 17;118(6):767-80
references: 15369675
references: Nucl Med Biol. 2010 Jan;37(1):57-65
references: 20122669
references: Traffic. 2002 May;3(5):311-20
references: 11967125
references: J Cell Biol. 1993 Dec;123(5):1107-17
references: 8245121
references: Cancer Invest. 2001;19(4):424-36
references: 11405181
references: Clin Chim Acta. 1966 Sep;14(3):361-6
references: 5970965
references: Biomaterials. 2012 Jun;33(18):4608-17
references: 22459195
references: J Cell Sci. 2001 Oct;114(Pt 20):3737-47
references: 11707525
references: FASEB J. 2010 Jun;24(6):1866-78
references: 20097877
references: Dalton Trans. 2009 Jul 21;(27):5395-400
references: 19565091
references: J Virol. 2008 Oct;82(19):9505-12
references: 18667513
references: J Cell Biol. 2010 Nov 1;191(3):615-29
references: 21041450
references: J Pharmacol Exp Ther. 2003 Sep;306(3):1058-67
references: 12808004
references: Biochim Biophys Acta. 1993 Sep 19;1151(2):201-15
references: 8373796
references: Science. 2004 Mar 19;303(5665):1818-22
references: 15031496
references: Pharm Res. 1998 Oct;15(10):1507-19
references: 9794491
references: J Biol Chem. 1988 Dec 15;263(35):18911-9
references: 3143719
references: Breast Cancer Res. 2002;4(3):95-9
references: 12052251
references: Nat Cell Biol. 2001 May;3(5):473-83
references: 11331875
references: Pharmacol Rev. 1999 Dec;51(4):691-743
references: 10581328
references: Nat Rev Drug Discov. 2010 Aug;9(8):615-27
references: 20616808
references: Nat Rev Mol Cell Biol. 2005 Feb;6(2):112-26
references: 15687999
references: J Control Release. 2012 Jun 10;160(2):117-34
references: 22484195
references: Nature. 1999 Feb 18;397(6720):621-5
references: 10050856
references: Nat Rev Cancer. 2005 Mar;5(3):161-71
references: 15738981
references: FASEB J. 2011 Jan;25(1):280-9
references: 20876209
references: Nat Rev Drug Discov. 2008 Mar;7(3):205-20
references: 18309312
references: Clin Cancer Res. 2008 Mar 1;14(5):1310-6
references: 18316549
references: Prog Lipid Res. 2005 Jan;44(1):68-97
references: 15748655
references: Clin Cancer Res. 2005 May 1;11(9):3567-73
references: 15867261
references: Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6944-9
references: 16203786
references: Cell. 1992 Feb 21;68(4):673-82
references: 1739974
references: J Biol Chem. 1996 Aug 30;271(35):21604-13
references: 8702948
references: Biochem J. 1990 Aug 15;270(1):97-102
references: 2204342
references: Biochim Biophys Acta. 2003 Jan 10;1609(1):102-8
references: 12507764
references: Theranostics. 2011;1:371-80
references: 22211143
references: Nat Rev Drug Discov. 2005 Feb;4(2):145-60
references: 15688077